Amgen, J&J settle sales-discount lawsuit

Amgen agreed to pay $200 million to settle an antitrust lawsuit by Johnson & Johnson's Ortho Biotech unit, putting to rest 2½ years of legal wrangling over Amgen's sales of its oncology products Aranesp, Neupogen, and Neulasta. Report